Precision Treatment Seen to Improve Response in Eligible Patients with Advanced Prostate and Other Cancers

Precision Treatment Seen to Improve Response in Eligible Patients with Advanced Prostate and Other Cancers
Patients with advanced cancers have longer responses to treatment when those treatments are tailored to the individual as opposed to receiving conventional therapies, according to the results of a clinical trial presented at the recent Molecular Analysis for Personalised Therapy (MAP) conference in London. The study enrolled patients with a number of advanced cancers, including prostate, breast, lung, head and neck, bladder, stomach, and bowel cancer, and is the first of its kind to demonstrate that precision medicine can increase the time it takes for a tumor to grow back, and that this holds true in different types of cancer. "This is the first precision medicine trial to show that analysing a person's DNA improves treatment options for patients with late stage cancer," Jean Charles Soria, the trial's principal investigator with the Gustave Roussy Cancer Campus, in France, said in a press release. "And these results are particularly exciting because in some cases we were testing experimental drugs, and found that we could slow down the growth of tumours in around one in five patients with advanced cancer." The trial, conducted at the Paris-area campus, enrolled 1,110 patients with advanced cancer, who had their genes mapped to look for mutations that could be targeted with drugs, including experimental therapies. All participants had already tried three or more cancer therapies, and had no other treatment options available. Researchers found that 411 patients had potentially faulty molecules to target, and experimental drugs were ideal to target such molecul
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *